Home » Topics » BioWorld Science

BioWorld Science
RSS

FK-506 undergoes phase II trials

June 28, 1996

Adenosine A3 antagonists from Merck & Co.

June 28, 1996

Eisai's ER-27319: Potential in treating allergic diseases

June 28, 1996

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Abbott discloses 5-lipoxygenase inhibitors

June 28, 1996

Leukotriene biosynthesis inhibitors from Merck Frosst

June 28, 1996

CRF earns positive results in phase I/II

June 28, 1996

Proctor & Gamble acquires Dura products

June 28, 1996

Cypros is granted U.S. patent for CPC-211 dosing regimen

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...